BELITE BIO, INC Logo

BELITE BIO, INC

Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.

BLTE | US

Overview

Corporate Details

ISIN(s):
US07782B1044
LEI:
Country:
United States of America
Address:
12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. The company's primary targets include atrophic age-related macular degeneration (specifically Geographic Atrophy, or GA) and Stargardt disease (STGD1). Its therapeutic pipeline is built on a proprietary portfolio targeting Retinol Binding Protein 4 (RBP4). The lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins that contribute to disease progression. Tinlarebant is in late-stage development with multiple Phase 3 trials and has received numerous regulatory designations, including Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations in the U.S. and other key markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BELITE BIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BELITE BIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BELITE BIO, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.